

## Product Information

# *o*-Phenylenediamine


Tablet, 20 mg substrate per tablet

**P5412**

## Product Description

CAS Registry Number: 95-54-5  
(*o*-Phenylenediamine component)Synonyms: 1,2-benzenediamine,<sup>1</sup> OPD  
(*o*-Phenylenediamine component)Molecular Formula: C<sub>6</sub>H<sub>8</sub>N<sub>2</sub>  
(*o*-Phenylenediamine component)Molecular Weight: 108.14  
(*o*-Phenylenediamine component)

*o*-Phenylenediamine (OPD) is a chromogenic substrate that is suitable for use in ELISA procedures that utilize horseradish peroxidase (HRP) conjugates.<sup>2,3</sup> This substrate produces a soluble end product that is orange-brown in color and can be read spectrophotometrically at 450 nm. The OPD reaction may be stopped with 3 M HCl or 3 M H<sub>2</sub>SO<sub>4</sub> solution, and read at 492 nm.



The OPD oxidation product that HRP produces is 2,3-diaminophenazine, which has been characterized by melting point, mass spectrometry, and NMR.<sup>4,5</sup>

Several publications,<sup>6-12</sup> theses,<sup>13,14</sup> and dissertations<sup>15,16</sup> have cited use of product P5412 in their research protocols.

## Reagent

P5412 is supplied as 50 tablets (50TAB) or 100 tablets (100TAB) per box, individually foil wrapped for ease of use, storage, and safety. Each tablet weighs ~45 mg (range 40-50 mg) and contains 20 mg of substrate.

One tablet, dissolved in 10 mL of water, gives a solution with a pH of 9.0 (range 8.5-9.5). The background absorbance of this solution cannot be more than 0.04.

## Precautions and Disclaimer

This product is for R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Storage/Stability

Store tablets at 2-8 °C. Protect from heat, light, and moisture. Allow to reach room temperature before use. Solutions should be freshly prepared.

## Preparation Instructions

1. Dissolve one tablet in 0.05 M phosphate-citrate buffer, pH 5.0, to the desired concentration. Typically, an OPD concentration of 0.4 mg/mL is used.
2. Add 40 µL of fresh 30% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, such as Cat. No. H1009) per 100 mL of substrate buffer solution, immediately prior to use.

**Note on buffer:** Phosphate-citrate buffer capsules containing sodium perborate (such as Cat. No. P4922) may be used. With these capsules, adding H<sub>2</sub>O<sub>2</sub> to the substrate solution is not necessary, since sodium perborate is a substitute for hydrogen peroxide.

## Troubleshooting

### If background is too high:

1. Use a blocking step prior to the application of the primary antibody. Normal serum (5% v/v) from the same species as the host of the secondary antibody generally produces the best results.

2. Additional blocking agents for an ELISA are:
  - 0.05% TWEEN® 20 in 0.01 M phosphate buffered saline (PBS), pH 7.4 (such as Cat. No. P3563)
  - PBS with 1% bovine serum albumin (BSA) containing 0.05% TWEEN® 20
  - 3% nonfat-dried milk in PBS (such as Cat. No. P2194). **Do not use milk as a blocking agent when using avidin-biotin systems.**
3. Use 0.05% TWEEN® 20 in all washing and antibody diluent buffers.
4. Run control wells without the primary antibody to check for non-specific reactivity of the secondary antibody.
5. Titer the primary antibody and the conjugate to optimize working dilutions.

#### If no color develops, or the color is too faint:

1. Adjust the concentration of the primary antibody.
2. Adjust the concentration of the secondary antibody.
3. Determine if the enzyme conjugate is active by mixing a small sample of substrate and conjugate together in a test tube.
4. Increase the reaction time or temperature.
5. Adjust the concentration of the coating antigen.
6. Consider using an amplification system such as avidin-biotin.

## References

1. *The Merck Index*, 12th ed., Entry# 7438 (1996).
2. Wolters, G. *et al.*, *J. Clin. Path.*, **29(10)**, 873-879 (1976).
3. Bovaird, J.H. *et al.*, *Clin. Chem.*, **28(12)**, 2423-2426 (1982).
4. Tarcha, P.J. *et al.*, *Anal. Biochem.*, **165(1)**, 230-233 (1987).
5. Bystryak, S.M., and Mekler, V.M., *Anal. Biochem.*, **202(2)**, 390-393 (1992).
6. Park, H.-M. *et al.*, *J. Vet. Med. Sci.*, **61(9)**, 995-1000 (1999).
7. Guo, F.C., and Woo, P.T.K., *Dis. Aquat. Org.*, **61**, 175-178 (2004).
8. van Dop, W.A. *et al.*, *Gastroenterology*, **139(5)**, 1665-1676 (2010).
9. Sroka, J. *et al.*, *Ann. Agric. Environ. Med.*, **18(2)**, 335-339 (2011).

10. Li, J. *et al.*, *Plant Cell*, **23(12)**, 4411-4427 (2011).
11. Weng, L. *et al.*, *EMBO J.*, **33(18)**, 2098-2112 (2014).
12. Pham, N.D. *et al.*, *J. Biol. Chem.*, **292(23)**, 9637-9651 (2017).
13. Ho, Man Ki Maggie, "Factors Contributing to Altered Insulin Levels of PWD/PhJ And WSB/EiJ Wild-Derived Inbred Mice". University of British Columbia, M.Sc. thesis, p. 32 (2014).
14. Rezai, Kamran, "Investigating the Functional Consequence of Pik3c2b Ablation in a Skeletal Muscle Model". University of Toronto, M.Sc. thesis, p. 47 (2016).
15. Rudge, Helen Janet, "Characterisation of Murine Gammaherpesvirus-68 Alkaline Nuclease". University College London, Ph.D. dissertation, p. 98 (2003).
16. Roberts, Helen Michelle, "Neutrophil Function in Chronic Inflammatory Disease States". University of Birmingham, Ph.D. dissertation, p. 80 (2016).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

## Terms and Conditions of Sale

Warranty, use restrictions, and other conditions of sale may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2018-2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.  
P5412pis Rev 01/23 CMH,RXR,GCY,MAM

